Home Stock

Stock Research: Aktis Oncology

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Aktis Oncology

NSQ:AKTS US00973N1028
31
  • Value
    79
  • Growth
    17
  • Safety
    Safety
    16
  • Combined
    23
  • Sentiment
    69
  • 360° View
    360° View
    31
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

ATech (Parent) Resolution Corp., formerly Akoustis Technologies, Inc., is not engaged in any business operating activity and has no assets. In the last fiscal year, the company had a market cap of $0 million, profits of $-1 million, revenue of $27 million, and 117 employees.

more

ANALYSIS: With an Obermatt 360° View of 31 (better than 31% compared with alternatives), overall professional sentiment and financial characteristics for the stock Aktis Oncology are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half the metrics below and half above average for Aktis Oncology. The consolidated Value Rank has an attractive rank of 79, which means that the share price of Aktis Oncology is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is lower than for 79% of alternative stocks in the same industry. The consolidated Sentiment Rank has a good rank of 69, which means that professional investors are more optimistic about the stock than for 69% of alternative investment opportunities. But the consolidated Growth Rank has a low rank of 17, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth, and stock returns. The consolidated Safety Rank has a riskier rank of 16, meaning the company has a riskier financing structure than 84 comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank Analyst Opinions
Country USA
Industry Biotechnology
Size X-Small
Website aktisoncology.com
Index
NASDAQ
Aktis Oncology stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 3-Nov-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
79 87 61 41
Growth
17 23 57 63
Safety
Safety
16 1 46 70
Sentiment
69 11 29 67
360° View
360° View
31 12 46 85
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
83 85 86 84
Opinions Change
50 50 50 50
Pro Holdings
n/a 5 25 67
Market Pulse
81 4 12 20
Sentiment
69 11 29 67
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
79 87 61 41
Growth
17 23 57 63
Safety Safety
16 1 46 70
Combined
23 23 61 65
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
34 100 65 25
Price vs. Earnings (P/E)
67 24 24 24
Price vs. Book (P/B)
62 96 92 64
Dividend Yield
1 1 1 1
Value
79 87 61 41
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
73 55 100 98
Profit Growth
48 92 72 30
Capital Growth
11 4 65 87
Stock Returns
28 3 3 3
Growth
17 23 57 63
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
72 1 42 100
Refinancing
33 4 79 63
Liquidity
3 7 7 15
Safety Safety
16 1 46 70

Similar Stocks

Discover high‑ranked alternatives to Aktis Oncology and broaden your portfolio horizons.

Global Payments

NYQ:GPN
Country: USA
Industry: Other Financial Services
Size: X-Large
Full Stock Analysis

AngloGold Ashanti

NYQ:AU
Country: USA
Industry: Gold Production
Size: X-Large
Full Stock Analysis

Toll Brothers

NYQ:TOL
Country: USA
Industry: Homebuilding
Size: X-Large
Full Stock Analysis

Cognizant Technology

NSQ:CTSH
Country: USA
Industry: IT Consulting & oth. Services
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

With good value and positive sentiment, but low growth and risky financing, this combination is generally dangerous as debt requires growth to sustain it. Only investors with a strong belief in future growth potential and a high-risk tolerance should consider this stock.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews